IP Library Granted Patent US 12,290,578
Granted Patent B2
US 12,290,578 · App. 18/450,873 · Granted May 6, 2025

Coupling agent produced from naturally fermented and sustainable additives

Inventors: Jon Wiesman (York, PA); George Deckner (Cincinnati, OH)
Assignee: Wiesman Holdings, LLC
A61K49/226A61K31/045A61K47/02A61K47/10A61K47/183A61K47/24A61K47/32A61K47/36
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,290,578
App. No.
18/450,873
Granted
May 6, 2025
Kind
B2
Abstract

A coupling agent composition is provided and includes a plurality of non-toxic components in an amount equal to or greater than 97 weight percent (wt %). The coupling agent composition includes a carrier of water, at least one water soluble polyol selected from the group consisting of propanediol, pentylene glycol, and butylene glycol in an amount of from about 1.0 to about 20.0 wt %, a thickening agent in an amount of about 0.05 to about 5.00 wt %, and a balance of incidental impurities.

Claims (20)

1. A coupling agent composition comprising:

a plurality of non-toxic components in an amount equal to or greater than 97 weight percent (wt %) of the composition by volume, the plurality of non-toxic components comprising:

a carrier of water;

at least one water soluble polyol selected from the group consisting of propanediol, pentylene glycol, and butylene glycol in an amount of from about 1.0 to about 20.0 wt %;

a thickening agent in an amount of about 0.05 to about 5.00 wt %; and

a remainder of the composition containing a balance of incidental impurities.

2. The composition according to claim 1 , wherein the at least one water soluble polyol is selected from the group consisting of 1,3-propanediol, 1,5-pentylene glycol, and 1,3-butylene glycol.

3. The composition according to claim 1 , wherein the thickening agent is a non-toxic swellable polymer.

4. The composition according to claim 3 , wherein the thickening agent includes at least one cross-linked polymer selected from a group consisting of hydrophobic polyacrylate or hydrophilic polyacrylate.

5. The composition according to claim 4 , wherein the cross-linked polymer is acrylate/C10-30 alkyl acrylate crosspolymer.

6. The composition according to claim 5 , wherein the at least one cross-linked polymer is in an amount of from 0.05 to 1.0 weight percent by volume.

7. The composition according to claim 1 , wherein the viscosity of the composition is 75,000-90,000 centipoise.

8. The composition according to claim 1 , wherein the plurality of non-toxic components further includes a naturally derived soluble polymer additive selected from a group consisting of xanthan gum, guar, locust bean, sodium hyaluronate, carrageenan, sodium alginate, acacia, tara gum, tamarind seed, mannan, succinoglycan, and scleroglucan.

9. The composition according to claim 8 , further comprising a biocide agent selected from the group consisting of phenoxyethanol, benzyl alcohol, caprylyl glycol, ethylhexylglycerin, decylene glycol, and 1,2-hexanediol.

10. The composition according to claim 9 , further comprising a neutralizing agent selected from a group consisting of sodium hydroxide, triethanolamine, tromethamine, arginine, and lysine.

11. The composition according to claim 10 , further comprising a chelating agent selected from a group consisting of disodium EDTA and sodium phytate.

12. The composition according to claim 1 , wherein the at least one naturally derived water soluble polyol is processed from a fermentation or enzymatic synthesis.

13. The composition according to claim 12 , wherein the fermentation or enzymatic synthesis is a natural chemical process using bacteria or yeast to convert organic materials.

14. The composition according to claim 1 , wherein a viscosity of the composition is 25000-100000 centipoise.

15. The composition according to claim 1 , wherein the plurality of non-toxic components is propylene glycol free.

Assignments (3)
SECURITY INTEREST Recorded Jan 30, 2026
From: WIESMAN HOLDINGS, LLC; HR PHARMACEUTICALS LLC
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 073646/0851 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 30, 2023
From: WIESMAN, JON; DECKNER, GEORGE
To: HR PHARMACEUTICALS, INC.
Reel/Frame 064754/0554 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 30, 2023
From: HR PHARMACEUTICALS, INC.
To: WIESMAN HOLDINGS, LLC
Reel/Frame 064783/0654 →
Continuity (4)
Continuation 17561171 · Dec 23, 2021
Continuation 16848502 · Apr 14, 2020
Continuation 15297762 · Oct 19, 2016
Related Publication 20230390420A1 · Dec 7, 2023
References Cited (25)
US 3304262A · Corey · 1967 [cited by applicant]
US 3621709A · Frey · 1971 [cited by applicant]
US 3740421A · Schmolka et al. · 1973 [cited by applicant]
US 3826127A · Molina · 1974 [cited by applicant]
US 4002221A · Buchalter · 1977 [cited by applicant]
US 4365516A · Molina · 1982 [cited by applicant]
US 5246490A · Kehoe et al. · 1993 [cited by applicant]
US 5522878A · Montecalvo · 1996 [cited by applicant]
US 6302848B1 · Larson et al. · 2001 [cited by applicant]
US 8133516B2 · Lauer · 2012 [cited by applicant]
US 8618175B2 · Heinar · 2013 [cited by applicant]
US 20050215908A1 · Chew et al. · 2005 [cited by applicant]
US 20060246111A1 · Smith · 2006 [cited by applicant]
US 20090155325A1 · Wenzel et al. · 2009 [cited by applicant]
US 20100215700A1 · Moaddel et al. · 2010 [cited by applicant]
US 20110229446A1 · Roman et al. · 2011 [cited by applicant]
US 20120114584A1 · Woghiren et al. · 2012 [cited by applicant]
US 20120150033A1 · Rauch · 2012 [cited by applicant]
WO 2005004972A1 · 2005 [cited by applicant]
WO 2005004982A2 · 2005 [cited by applicant]
WO 2012009794A1 · 2012 [cited by applicant]
PCT International Search Report and Written Opinion, Application No. PCT/US2017/057344, Dated: Mar. 16, 2018, 10 pages. [cited by applicant]
Enhancement of (R)-1,3-Butanediol Production by Engineered [cited by applicant]
California Proposition 65 (1986) (see http://oehha.ca.gov/proposition-65/proposition-65-list). [cited by applicant]
Doelker, E., “Water Swollen Cellulose Derivatives in Pharmacy”, Hydrogels in Medicine and Pharmacy: vol. 2—Polymers, edited by Peppas, N.A., CRC Press Inc., Boca Raton, Florida, 1987, p. 124. [cited by applicant]